Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 163

1.

Individual differences in the processing of smoking-cessation video messages: An imaging genetics study.

Shi Z, Wang AL, Aronowitz CA, Romer D, Langleben DD.

Biol Psychol. 2017 Jul 28;128:125-131. doi: 10.1016/j.biopsycho.2017.07.019. [Epub ahead of print]

PMID:
28757070
2.

Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis.

Langleben D, Orfanos S.

Pulm Circ. 2017 Jun 20:2045893217714231. doi: 10.1177/2045893217714231. [Epub ahead of print]

PMID:
28632001
3.

Right ventricular ST-elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension.

Zhan Y, Burstein B, Abualsaud AO, Nosair M, Hirsch AM, Lesenko L, Langleben D.

Pulm Circ. 2017 Apr-Jun;7(2):555-558. doi: 10.1177/2045893217704435. Epub 2017 May 12.

4.

Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.

Guina J, Roy S, Gupta A, Langleben DD, Elman I.

Hum Psychopharmacol. 2017 Jul;32(4). doi: 10.1002/hup.2604. Epub 2017 Jun 1.

PMID:
28573760
5.

Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial.

Harel F, Langleben D, Provencher S, Fournier A, Finnerty V, Nguyen QT, Letourneau M, Levac X, Abikhzer G, Guimond J, Mansour A, Guertin MC, Dupuis J.

Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1136-1144. doi: 10.1007/s00259-017-3655-y. Epub 2017 Feb 24.

6.

Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.

Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA.

J Heart Lung Transplant. 2017 May;36(5):509-519. doi: 10.1016/j.healun.2016.12.012. Epub 2016 Dec 24.

7.

Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.

Guina J, Gupta A, Langleben DD, Elman I.

J Clin Psychiatry. 2016 Dec;77(12):e1650-e1651. doi: 10.4088/JCP.16l10705. No abstract available.

8.

Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Constance C, Trudeau L, Jolicoeur EM, Langleben D, Rivard A, Chehayeb R, Côté MA, Delgado D.

Leukemia. 2017 Mar;31(3):771-772. doi: 10.1038/leu.2016.336. Epub 2016 Dec 2. No abstract available.

PMID:
27909345
9.

Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.

Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA.

Respir Med. 2017 Jan;122 Suppl 1:S18-S22. doi: 10.1016/j.rmed.2016.11.001. Epub 2016 Nov 5.

PMID:
27887774
10.

Polygraphy and Functional Magnetic Resonance Imaging in Lie Detection: A Controlled Blind Comparison Using the Concealed Information Test.

Langleben DD, Hakun JG, Seelig D, Wang AL, Ruparel K, Bilker WB, Gur RC.

J Clin Psychiatry. 2016 Oct;77(10):1372-1380. doi: 10.4088/JCP.15m09785.

PMID:
26794034
11.

Pregnancy as a possible trigger for heritable pulmonary arterial hypertension.

Limoges M, Langleben D, Fox BD, Shear R, Wieczorek P, Rudski LG, Hirsch AM, Schlesinger RD, Lesenko L.

Pulm Circ. 2016 Sep;6(3):381-3. doi: 10.1086/686993.

12.

Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cues.

Regier PS, Monge ZA, Franklin TR, Wetherill RR, Teitelman A, Jagannathan K, Suh JJ, Wang Z, Young KA, Gawrysiak M, Langleben DD, Kampman KM, O'Brien CP, Childress AR.

Addict Biol. 2016 Sep 22. doi: 10.1111/adb.12445. [Epub ahead of print]

PMID:
27654662
13.

Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis.

Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR.

Can J Cardiol. 2016 Dec;32(12):1520-1530. doi: 10.1016/j.cjca.2016.03.004. Epub 2016 Mar 17. Review.

PMID:
27378592
14.

Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.

Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, Klinger JR.

Chest. 2017 Feb;151(2):468-480. doi: 10.1016/j.chest.2016.05.024. Epub 2016 Jun 2. Review.

15.

Targeting modulates audiences' brain and behavioral responses to safe sex video ads.

Wang AL, Lowen SB, Shi Z, Bissey B, Metzger DS, Langleben DD.

Soc Cogn Affect Neurosci. 2016 Oct;11(10):1650-7. doi: 10.1093/scan/nsw070. Epub 2016 May 19.

16.

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.

Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M.

Lancet Respir Med. 2016 May;4(5):361-71. doi: 10.1016/S2213-2600(16)30019-4. Epub 2016 Apr 8.

PMID:
27067479
17.

Playing it safe: a video game probing the relationship between addiction, gender, and avoidance.

Shi Z, Wang AL, Langleben DD.

J Clin Psychiatry. 2016 Mar;77(3):395-7. doi: 10.4088/JCP.16com10752. No abstract available.

18.

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators.

N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.

19.

Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.

Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1345-54. doi: 10.1164/rccm.201501-0196OC.

20.

Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial.

Granton J, Langleben D, Kutryk MB, Camack N, Galipeau J, Courtman DW, Stewart DJ.

Circ Res. 2015 Sep 11;117(7):645-54. doi: 10.1161/CIRCRESAHA.114.305951. Epub 2015 Jul 20.

Supplemental Content

Loading ...
Support Center